Monthly Archives: March 2020

Asia Cannabis Corp. Confirms Patent Application Filed by Swysh Inc. in Relation to Anti-Viral Treatments

CALGARY, AB / ACCESSWIRE / March 30, 2020 / Asia Cannabis Corp. ("ACC" or the "Company") (CSE:ASIA) announced the following corporate developments today:

On March 13, 2020, ACC announced that it had entered into an agreement with Swysh Inc., an Alberta Research and Development company ("Swysh") focused on specific cannabinoid-based research and that owns proprietary technology and related intellectual property aimed at providing the basis for creation of systemic and topical treatments for a variety of external and internal conditions and ailments, including a number of anti-viral and preventative health-care applications. This agreement grants a license to ACC to deploy the technology for the purpose of completing further research, development, testing and additional validation and establishment of practical applications with a view to commercialization of the technology in the greater region of Asia.

Today, the Company and Swysh confirm that a patent application has now been filed by agents for Swysh with the United States Patent Office in respect of new and unique Cannabis sativa lines, extracts and methods for their use to inhibit the levels of ACE2 receptor in oral, lung and intestinal epithelial tissues to prevent entry of SARS-CoV-2 and related viruses, to treat the cytokine storm that precedes and underlies acute respiratory distress syndrome in COVID-19 and other diseases, and to affect viral life cycle processes. Extracts of novel hemp lines can be combined with anti-viral agents and anti-inflammatory extracts of turmeric, chamomile, sage, fennel, ginger, rosehip or other herbs, as well as probiotics to increase their efficacy.

Dr. Igor Kovalchuk, a director of ACC and the Chief Executive Officer, director and controlling shareholder of Swysh stated: "Swysh has been actively researching and developing the protocols associated with the creation of these new Cannabis sativa lines, extracts and their related applications for some time. It is extremely serendipitous and fortunate that we have been able to make these advances relative to specialized viral treatments at a time when a significant outbreak occurs such as we see in the Covid-19 crisis. We are actively and aggressively moving ahead with further research, and next steps include substantiation of our findings through additional molecular research, including cell lines and viral replicons as well as preparation and submission of application for conducting clinical trials. Through its license agreement with Swysh, we believe the ACC will be in a position to provide key assistance in validating these treatments by utilizing the resources and skills of its academic and business partners in the Asian region."

About ACC:

ACC is an early stage international Agri-technology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of license agreements with InPlanta Biotechnologies Inc. and Swysh Inc.

In conjunction with both InPlanta and Swysh, the Company is developing varieties of hemp with superior growth and production characteristics in the various environments found in the licensed territories. With the data and associated knowledge gained from these activities, the Company intends to leverage the technology to develop a portfolio of strategic hemp investments to take advantage of both the changing social climate relative to hemp use and the historic acceptance of the use of these products and their derivatives in certain of the jurisdictions granted under the License Agreements.

For further information, contact:

David Pinkman
Chief Executive Officer
(403) 863-6034

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: active research and development of the protocols associated with the creation of new Cannabis sativa lines, commencement of testing activities in relation thereto, grant of patent protection in respect of the novel traits identified by Swysh, commercial production of any related products and treatments cased on these developments, and future expansion plans including development of the cultivation, production, industrialization and marketing of hemp-based products for commercial and scientific purposes.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Asian and international medical products market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of hemp and hemp-related products in Asia and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

SOURCE: Asia Cannabis Corp.

ReleaseID: 583168

Duos Technologies Group Reports Fourth Quarter and Full Year 2019 Results

Company Drives Record Quarterly and Annual Performance Supporting Return to Profitability

JACKSONVILLE, FL / ACCESSWIRE / March 30, 2020 / Duos Technologies Group, Inc. ("Duos" or the "Company") (NASDAQ:DUOT), a provider of intelligent security analytical technology solutions, reported financial results for the fourth quarter and full year ended December 31, 2019.

Fourth Quarter 2019 and Recent Operational Highlights

Successfully listed onto the Nasdaq Capital Market and began trading under the ticker symbol "DUOT" effective February 13, 2020. In connection with the listing, Duos management rang the ceremonial Nasdaq Opening Bell on February 21, 2020.
Also in connection with being listed on the Nasdaq, completed underwritten public offering of 1,542,188 shares of common stock at an offering price of $6.00 per share, resulting in total gross proceeds of $9.25 million, which includes the exercise of its over-allotment option prior to deducting underwriting discounts, commissions and offering expenses payable by the Company.
Implemented first full-scale Rail Inspection Portal (rip®) in record time for CSX Transportation, Inc., one of the seven Class 1 Railroad operators who own and operate a combined 140,000 miles of rail track.
Substantially completed another rip® with a different customer, which is scheduled for final acceptance at a site in Mexico within the next 60 days.
Completed engineering and the launch of a beta test installation of a state-of-the-art, 3D version of Duos' pantograph inspection system (apis®), at a transit rail location in Chicago.
Completed installation of an industrial portal for tank car inspection in Michigan.

Completed next generation centraco® platform designed to provide additional security and logistics for a banking group.
Successfully transitioned the Company's artificial intelligence (AI) models to its new, proprietary truevue360 platform.

Fourth Quarter 2019 Financial Results

It should be noted that the following Financial Results represent the consolidation of the Company with its subsidiaries Duos Technologies, Inc. and truevue360™.

Total revenue increased 125% to $5.75 million compared to $2.56 million in the same quarterly period. This significant increase in total revenue was partially the result of timing shifts from previous quarters and was also driven by the current strength of the projects portion of the Company's business with additional contributions from maintenance and technical support as well as its IT asset management (ITAM) division.

Gross profit increased 176% to $3.15 million (55% of total revenue) compared to $1.14 million (45% of total revenue) in the same quarterly period last year. The increase in gross profit was the result of the increase in project revenues previously mentioned and the positive effect of continuing revenue increases from new projects.

Operating expenses increased 28% to $2.52 million from $1.98 million in the same quarterly period last year reflecting the increase in resources related to the increase in revenues for the period as well as additional resources related to the new truevue360™ AI subsidiary. The increase in operating expenses was mainly driven by selling and marketing expenses, which increased in line with the Company's investment in resources to grow the business.

Net income totaled $592,000, an increase from net loss of $836,000 in the same quarter a year-ago. The improvement in net income was primarily attributable to the increase in project revenues previously mentioned more than covering a planned increase in operating expenses recorded in the same period.

Full Year 2019 Financial Results

Total revenue increased 13% to $13.64 million compared to $12.05 million in the same period last year. The steady increase in total revenue was driven by the current strength of the projects portion of the Company's business with additional contributions from maintenance and technical support as well as its ITAM division. The maintenance and technical support revenues were driven by successful completion of projects and represent services and technical support for those installations. The expectation is that revenues from this area will continue to grow based on the success of multiple installations in 2019.

Gross profit increased 25% to $6.48 million (48% of total revenue) compared to $5.20 million (43% of total revenue) in the same period last year. The increase in gross profit was the result of the increase in project revenues previously mentioned and the positive effect of continuing revenue increases from new projects. The Company anticipates overall gross margins to continue to improve in the coming year driven by higher sales from both existing and new customers and certain "economies of scale" from larger projects. The increase in revenues will positively impact recurring revenue from maintenance and technical support with a resulting increase in gross margin.

Operating expenses increased 31% to $8.89 million compared to $6.77 million in the same period last year reflecting the increase in resources related to the increase in revenues for the period as well as additional resources related to the new truevue360™ AI subsidiary. Selling and marketing expenses increased in line with the Company's investment in resources to grow the business. The Company also increased human resources head count for the development of the new truevue360™ AI platform as well as operational costs for the new laboratory for training the machine learning systems. This rate of increase is expected to slow in 2020. Other general and administrative costs were higher as the result of additional business and non-project related travel.

Net loss totaled $2.47 million, an increase from net loss of $1.58 million in the same period a year-ago. The increase in net loss was primarily attributable to an increase in expenses related to truevue360™, including software development contract staff in Europe and machine learning trainers at the Florida R&D center.

Financial Outlook

The Company has previously provided revenue guidance of $20 million for 2020, which would represent an approximate 47% increase over the $13.6 million recorded in 2019. The Company's guidance is based on contracts in backlog and near-term pending orders that are already performing or scheduled to be executed throughout the course of 2020.

The majority of the Company's customers, and by proxy the Company, have been identified as essential to continued infrastructure viability. Consequently, Duos' workforce is considered "essential" under the rule. Accordingly, while there is not a tangible reason to reduce revenue guidance for the year at this point, the Company cautions that because of the substantially increased global uncertainty, particularly due to the COVID-19 pandemic, revenues in the first half of the year could be substantially below those of the comparable period in 2019 due to potential delays in project execution resulting from the restrictive travel environment currently in place.

Management Commentary

"We ended the year on a high note, with a record performance in the fourth quarter driven by strong performances in each of our operating divisions," said Duos Chairman and CEO Gianni Arcaini. "Most notably, we closed agreements and completed a series of major project implementations toward the end of 2019, supporting our decision to allocate greater resources earlier in the year to meet this expected increase in demand. In Q4 we also achieved profitability thanks to the substantial gross margin increases we generated in the period. We expect to incrementally improve our fundamentals on an annual go-forward basis as we benefit from economies of scale through larger contracts as well as steady increases in recurring revenues from our maintenance and technical support division and the anticipated growth from our truevue360™ AI subsidiary.

"We began the new year with significant operating and sales momentum as well as an elevated company profile. In February we successfully raised over $9 million to support our future growth needs for the foreseeable future and also uplisted onto the Nasdaq Capital Market. With our new listing on a national exchange, we are eager to capitalize on the opportunity to more widely spread the Duos story to a new, broader audience. At the same time, with the current global economic crisis related to COVID-19, we anticipate an intra-year impact, which would result in possible shifting of revenues from the first half into the latter quarters of 2020. Fortunately, our supply chain was not affected, and our high-value IP revenue drivers are all controlled by the Company. We have also maintained consistent communications with our clients and put a plan in place to ensure ongoing business continuity. While we still expect to generate robust double-digit growth in 2020, we are refraining from providing updated annual revenue expectations until more reliable information becomes available."

Conference Call

The Company's management will host a conference call today, Monday, March 30, 2020 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss these results, followed by a question and answer period.

Date: Monday, March 30, 2020
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
U.S. dial-in: (877) 407-3088
International dial-in: +1 (201) 389-0927
Confirmation: 13700827

Please call the conference telephone number 5-10 minutes prior to the start time of the conference call. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Investor Relations at (949) 574-3860.

The conference call will be broadcasted live via telephone and available for online replay via the investor section of the Company's website here.

About Duos Technologies Group, Inc.

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc., provides advanced, analytical technology solutions with a strong portfolio of intellectual property. The Company's core competencies include intelligent technologies that combine machine learning, artificial intelligence and advanced video analytics that are delivered through its proprietary integrated enterprise command and control centraco® platform. The Company provides its broad range of technology solutions with an emphasis on mission critical security, inspection and operations within the rail transportation, retail, petrochemical, government, and banking sectors. Duos Technologies also offers professional and consulting services for large data centers. For more information, visit www.duostech.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause Duos Technologies Group, Inc.'s actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to, those described in Item 1A in Duos' Annual Report on Form 10-K, which is expressly incorporated herein by reference, and other factors as may periodically be described in Duos' filings with the SEC.
 

DUOS TECHNOLOGIES GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

 

 
For the Year Ended
 

 

 
December 31,
 

 

 
2019
 
 
2018
 

 

 
 
 
 
 
 

REVENUES:

 
 
 
 
 
 

Project

 

11,963,438
 
 

10,753,926
 

Maintenance and technical support

 
 
1,377,459
 
 
 
1,170,215
 

IT asset management services

 
 
300,418
 
 
 
124,478
 

 

 
 
 
 
 
 
 
 

Total Revenues

 
 
13,641,315
 
 
 
12,048,619
 

 

 
 
 
 
 
 
 
 

COST OF REVENUES:

 
 
 
 
 
 
 
 

Project

 
 
6,510,658
 
 
 
6,373,684
 

Maintenance and technical support

 
 
528,966
 
 
 
409,316
 

IT asset management services

 
 
120,253
 
 
 
61,396
 

 

 
 
 
 
 
 
 
 

Total Cost of Revenues

 
 
7,159,877
 
 
 
6,844,396
 

 

 
 
 
 
 
 
 
 

GROSS PROFIT

 
 
6,481,438
 
 
 
5,204,223
 

 

 
 
 
 
 
 
 
 

OPERATING EXPENSES:

 
 
 
 
 
 
 
 

Selling and marketing expenses

 
 
421,535
 
 
 
289,140
 

Salaries, wages and contract labor

 
 
5,570,140
 
 
 
4,299,799
 

Research and development

 
 
431,425
 
 
 
488,694
 

Professional fees

 
 
252,825
 
 
 
245,033
 

General and administrative expenses

 
 
2,212,035
 
 
 
1,451,461
 

 

 
 
 
 
 
 
 
 

Total Operating Expenses

 
 
8,887,960
 
 
 
6,774,127
 

 

 
 
 
 
 
 
 
 

LOSS FROM OPERATIONS

 
 
(2,406,522
)
 
 
(1,569,904
)

 

 
 
 
 
 
 
 
 

OTHER INCOME (EXPENSES):

 
 
 
 
 
 
 
 

Interest Expense

 
 
(69,322
)
 
 
(17,180
)

Other income, net

 
 
4,962
 
 
 
6,197
 

 

 
 
 
 
 
 
 
 

Total Other Income (Expense)

 
 
(64,360
)
 
 
(10,983
)

 

 
 
 
 
 
 
 
 

NET LOSS

 
 
(2,470,882
)
 
 
(1,580,887
)

 

 
 
 
 
 
 
 
 

Net loss applicable to common stock

 

(2,470,882
)
 

(1,580,887
)

 

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

Basic Net Loss Per Share

 

(1.25
)
 

(1.06
)

Diluted Net Loss Per Share

 

(1.25
)
 

(1.06
)

 

 
 
 
 
 
 
 
 

Weighted Average Shares-Basic

 
 
1,978,227
 
 
 
1,485,438
 

Weighted Average Shares-Diluted

 
 
1,978,227
 
 
 
1,485,438
 

DUOS TECHNOLOGIES GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

 

 
December 31,
 
 
December 31,
 

 

 
2019
 
 
2018
 

 

 
 
 
 
 
 

ASSETS

 
 
 
 
 
 

CURRENT ASSETS:

 
 
 
 
 
 

Cash

 

56,249
 
 

1,209,301
 

Accounts receivable, net

 
 
2,611,608
 
 
 
1,538,793
 

Contract assets

 
 
1,375,920
 
 
 
1,208,604
 

Prepaid expenses and other current assets

 
 
716,598
 
 
 
235,198
 

 

 
 
 
 
 
 
 
 

Total Current Assets

 
 
4,760,375
 
 
 
4,191,896
 

 

 
 
 
 
 
 
 
 

Property and equipment, net

 
 
260,181
 
 
 
204,226
 

Operating lease right of use asset

 
 
430,146
 
 
 

 

 

 
 
 
 
 
 
 
 

OTHER ASSETS:

 
 
 
 
 
 
 
 

Software Development Costs, net

 
 
20,000
 
 
 
40,000
 

Patents and trademarks, net

 
 
61,598
 
 
 
53,871
 

Total Other Assets

 
 
81,598
 
 
 
93,871
 

 

 
 
 
 
 
 
 
 

TOTAL ASSETS

 

5,532,300
 
 

4,489,993
 

 

 
 
 
 
 
 
 
 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

CURRENT LIABILITIES:

 
 
 
 
 
 
 
 

Accounts payable

 

2,641,437
 
 

1,416,716
 

Accounts payable – related parties

 
 
12,791
 
 
 
13,473
 

Notes payable – financing agreements

 
 
42,299
 
 
 
48,330
 

Notes payable – related parties, net of discounts

 
 
905,373
 
 
 

 

Notes payable, net of discounts

 
 

 
 
 

 

Line of credit

 
 
27,615
 
 
 
31,201
 

Payroll taxes payable

 
 
115,111
 
 
 
317,573
 

Accrued expenses

 
 
393,272
 
 
 
222,328
 

Current portion – financing lease agreements

 
 
45,072
 
 
 
 
 

Current portion-operating lease obligations

 
 
239,688
 
 
 

 

Contract liabilities

 
 
8,661
 
 
 
2,248,829
 

Deferred revenue

 
 
936,428
 
 
 
362,528
 

 

 
 
 
 
 
 
 
 

Total Current Liabilities

 
 
5,367,747
 
 
 
4,660,978
 

 

 
 
 
 
 
 
 
 

Finance lease payable

 
 
89,026
 
 
 

 

Operating lease obligations

 
 
202,797
 
 
 

 

 

 
 
 
 
 
 
 
 

Total Liabilities

 
 
5,659,570
 
 
 
4,660,978
 

 

 
 
 
 
 
 
 
 

Commitments and Contingencies (Note11)

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

STOCKHOLDERS' EQUITY (DEFICIT):

 
 
 
 
 
 
 
 

Preferred stock: $0.001 par value, 10,000,000 authorized, 9,485,000 shares available to be designated Series A redeemable convertible cumulative preferred stock, $10 stated value per share, 500,000 shares designated; 0 issued and outstanding at December 31, 2019 and December 31, 2018, convertible into common stock at $6.30 per share

 
 

 
 
 

 

Series B convertible cumulative preferred stock, $1,000 stated value per share, 15,000 shares designated; 1,705 and 2,830 issued and outstanding at December 31, 2019 and December 31, 2018, convertible into common stock at $0.50 per share

 
 
1,705,000
 
 
 
2,8300,000
 

 

 
 
 
 
 
 
 
 

Common stock: $0.001 par value; 500,000,000 shares authorized, 1,982,039 and 1,505,883 shares issued, 1,980,715 and 1,505,426 shares outstanding at December 31, 2019 and December 31, 2018, respectively

 
 
1,982
 
 
 
1,505
 

Additional paid-in capital

 
 
31,063,915
 
 
 
27,416,802
 

Total stock & paid-in-capital

 
 
32,770,897
 
 
 
30,248,307
 

Accumulated deficit

 
 
(32,740,715
)
 
 
(30,269,833
)

Sub-total

 
 
30,182
 
 
 
(21,526
)

Less: Treasury stock (1,324 and 457 shares of common stock

at December 31, 2019 and December 31, 2018, respectively)

 
 
(157,452
)
 
 
(149,459
)

 
 
 
 
 
 
 
 

Total Stockholders' Equity (Deficit)

 
 
(127,270
)
 
 
(170,985
)

 

 
 
 
 
 
 
 
 

Total Liabilities and Stockholders' Equity (Deficit)

 

5,532,300
 
 

4,489,993
 

DUOS TECHNOLOGIES GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 
For the Years Ended
 

 

 
December 31,
 

 

 
2019
 
 
2018
 

 

 
 
 
 
 
 

Cash from operating activities:

 
 
 
 
 
 

Net loss

 

(2,470,882
)
 

(1,580,887
)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 
 
 
 
 
 
 
 

Bad debt expense

 
 
220,405
 
 
 

 

Depreciation and amortization

 
 
184,620
 
 
 
98,922
 

Stock based compensation

 
 
44,874
 
 
 
447,826
 

Interest expense related to debt discounts

 
 
64,652
 
 
 

 

Changes in assets and liabilities:

 
 

 
 
 
 
 

Accounts receivable

 
 
(1,293,220
)
 
 
(1,240,489
)

Contract assets

 
 
(167,316
)
 
 
(784,811
)

Prepaid expenses and other current assets

 
 
(174,202
)
 
 
97,964
 

Operating lease right of use asset

 
 
(430,145
)
 
 

 

Accounts payable

 
 
1,224,720
 
 
 
604,096
 

Related payable-related party

 
 
(682
)
 
 
875
 

Payroll taxes payable

 
 
(202,462
)
 
 
168,125
 

Accrued expenses

 
 
203,861
 
 
 
(128,948
)

Operating lease obligation

 
 
442,485
 
 
 

 

Contract liabilities

 
 
(2,240,168
)
 
 
2,048,419
 

Deferred revenue

 
 
573,900
 
 
 
(76,379
)

 

 
 
 
 
 
 
 
 

Net cash used in operating activities

 
 
(4,019,560
)
 
 
(345,287
)

 

 
 
 
 
 
 
 
 

Cash flows from investing activities:

 
 
 
 
 
 
 
 

Software development costs

 
 

 
 
 
(60,000
)

Purchase of patents/trademarks

 
 
(13,095
)
 
 
(13,285
)

Purchase of fixed assets

 
 
(206,480
)
 
 
(212,393
)

 

 
 
 
 
 
 
 
 

Net cash used in investing activities

 
 
(219,575
)
 
 
(285,678
)

 

 
 
 
 
 
 
 
 

Cash flows from financing activities:

 
 
 
 
 
 
 
 

Repurchase of common stock

 
 
(7,993
)
 
 
(1,459
)

Repayments of line of credit

 
 
(3,586
)
 
 
(3,312
)

Repayments of related party notes

 
 
(80,000
)
 
 
(48,215
)

Repayments of notes payable

 
 
(262,500
)
 
 
 
 

Issuance cost

 
 
(20,000
)
 
 

 

Repayments of insurance and equipment financing

 
 
(266,132
)
 
 
(243,566
)

Payment of finance lease

 
 
(24,652
)
 
 

 

Proceeds from eqipment financing

 
 
102,928
 
 
 

 

Proceeds from notes payable-related parties

 
 
1,080,000
 
 
 

 

Proceeds from notes payable

 
 
250,000
 
 
 

 

Proceeds from warrants exercised

 
 
2,318,018
 
 
 
195,000
 

 

 
 
 
 
 
 
 
 

Net cash provided by (used in) financing activities

 
 
3,086,083
 
 
 
(101,552
)

 

 
 
 
 
 
 
 
 

Net decrease in cash

 
 
(1,153,052
)
 
 
(732,517
)

Cash, beginning of period

 
 
1,209,301
 
 
 
1,941,818
 

Cash, end of period

 
 
56,249
 
 
 
1,209,301
 

 

 
 
 
 
 
 
 
 

Supplemental Disclosure of Cash Flow Information:

 
 
 
 
 
 
 
 

Interest paid

 

6,320
 
 

7,411
 

 

 
 
 
 
 
 
 
 

Supplemental Non-Cash Investing and Financing Activities:

 
 
 
 
 
 
 
 

Common stock issued for accrued BOD fees

 

32,917
 
 

73,708
 

Common stock issued for accrued officer salary

 


 
 

72,292
 

Note issued for financing of insurance premiums

 

260,103
 
 

242,239
 

Debt discount on Notes issued

 

12,500
 
 


 

Note issued for equipment financing lease

 

55,822
 
 


 

Right of Use Asset and Liability

 

644,245
 
 


 

Relative fair value of warrant recorded as debt discount

 

146,779
 
 


 

CONTACT:

Corporate

Tracie Hutchins
Duos Technologies Group, Inc.
(904) 652-1601
tlh@duostech.com

Investor Relations

Matt Glover or Tom Colton
Gateway Investor Relations
(949) 574-3860
DUOT@GatewayIR.com

SOURCE: Duos Technologies Group, Inc.

ReleaseID: 583110

Dyadic Reports 2019 Year End Results and Recent Developments

New research license agreement with WuXi Biologics, a leading global CDMO
Two new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health company
Six funded research collaborations and one expanded collaboration signed in 2019
Expanded strategic R&D relationships to assist in the development of COVID-19 vaccine and antibodies
Expanded internal product and platform pipeline
Robust scientific data demonstrates C1's strong capabilities, new attributes, and broader market opportunities
Cash and investment grade securities of $36 million at year-end 2019

JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2019, and recent developments.

"I am pleased to report that 2019 was another successful year for Dyadic as we achieved several important scientific and business milestones and expanded our global presence. While still early in 2020, we are seeing continued momentum. During 2019, we entered into six new proof of concept research collaborations to express different types of biologic vaccines and drugs for both human and animal health and entered into two research licenses. As a result, Dyadic's pipeline of opportunities is getting larger and more diverse. Last week, we entered into a nonexclusive research license with WuXi Biologics, a leading global Contract Development Manufacturing Organization ("CDMO") and another fully funded feasibility study with a leading animal health company. We are now working with three of the top four animal health companies," said Mark Emalfarb, Dyadic's Chief Executive Officer.

He further commented, "To assist in the global fight against the COVID-19 pandemic, we are working with the Israel Institute for Biological Research ("IIBR"), Ufovax, a spin-off vaccine company of Scripps Research, as well as a group of coronavirus experts from Erasmus Medical Center, Utrecht University, and the University of Veterinary Medicine Hannover (TiHo) along with a clinical contract research organization, CR20. We expect to use C1 to express a growing number of potential coronavirus vaccine and antibody candidates for a number of different parties. Our involvement in these COVID-19 initiatives further highlights the broad application potential of our C1 technology by helping to immediately address the coronavirus outbreak, be better prepared for future infectious diseases, pandemic and epidemic outbreaks, and advance biopharmaceutical manufacturing to help speed up development, lower the cost and improve the performance of biologic vaccines and drugs to make healthcare more accessible and affordable to patients globally."

"Supporting our growth strategy is our robust scientific data, solid financial position with approximately $36 million in cash and investment grade securities, and on-going R&D collaborations funded by our partners. Our visibility in the investment community has significantly increased as well. In 2019, our shares were up-listed to the Nasdaq and we joined the Russell Microcap Index® further reinforcing the continued growth of our Company. We look forward to sharing additional new developments throughout the year as we remain confident in our vision of creating more efficient and commercially cost-effective healthcare solutions," concluded Mr. Emalfarb.

RECENT DEVELOPMENTS

Dyadic entered into a funded collaboration with another top four animal health company to engage in a feasibility study regarding the production of two proteins using our C1 platform. Three of the top four animal health companies are currently funding research programs to evaluate C1.
Dyadic entered into a nonexclusive research license with WuXi Biologics, one of the leading global Contract Development Manufacturing Organizations.
The Israel Institute for Biological Research has expanded its collaboration with the Company to explore the potential of C1 to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies ("mAbs") that may potentially help combat the COVID-19 outbreak.
Data presented at the 15th European Conference on Fungal Genetics ("ECFG15") demonstrated that Dyadic's C1 strain has been glyco-engineered to achieve a core human-like G2 glycan level over 76%. Data also showed excellent progress we made in reducing the extracellular protease background by 50 times in C1. The elimination of protease activity makes the C1 cell line more efficient and stable, leading to even higher expression levels and lower cost.
Dyadic entered into a new feasibility study with the University of Oslo on influenza vaccine.
In response to COVID-19, the Company submitted proposals to various funding agencies and parties to develop SARS-CoV-2 vaccine candidates up to and through a Phase 1 trial.

SCIENTIFIC ACHIEVEMENTS

Demonstrated further success of C1 with fermentation results of the ZAPI antigen against the Schmallenberg virus ("SBV") with a yield of 1,780 mg/l (time point 121h) or 17 times the initially targeted expression level or more than 35 times baculovirus, the next closest expression platform. In December, Dyadic received positive preliminary results for the ZAPI animal studies and expanded the funded research collaboration to express two additional proteins. Recent results shared with us from the ZAPI consortium indicated that Dyadic's C1 antigen demonstrated very strong performance in protecting both cattle and mice from the SBV. A publication reporting these results is expected to be available in the second quarter of 2020.
Dyadic extended its research and development contract through June 2022 with VTT Technical Research Centre of Finland Ltd ("VTT"). Data generated through the collaborative scientific research efforts has exceeded our initial expectations and produced record levels of productivity for several different types of proteins. This was demonstrated by the very high expression level reached of a full-length monoclonal antibody of approximately 24.5 grams per liter in seven days or approximately 3.5 grams per liter per day, well above the current industry average.
Data presented at the PEGS Lisbon conference demonstrated that our C1 strain has been glyco-engineered to achieve a core human-like G0 glycan level of about 95%.
In our collaboration with The Israel Institute for Biological Research, it used C1 technology to express a proprietary IIBR Fc-fusion enzyme. The recombinant IIBR Fc-fusion enzyme provided longer lasting protection against nerve agents such as sarin and VX gas than Acetyl Choline Esterase which is commonly used.
With regard to the Company's Sanofi collaboration, Dyadic has achieved or exceeded the targeted expression levels for a number of different types of biologic vaccines and drugs and we are currently in discussions regarding next steps.

2019 BUSINESS DEVELOPMENT HIGHLIGHTS

In 2019, we entered into six new proof of concept research collaborations including the Serum Institute of India, two leading animal health companies, and three top tier human health companies, as well as an expanded collaboration with ZAPI. In addition, we signed two sublicensing agreements and two non-exclusive research license agreements.

Dyadic announced a research and commercialization collaboration with the Serum Institute of India. Serum will apply Dyadic's C1 technology to express up to 12 proteins – eight MABs and four rVaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic's C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sublicense for each of the 12 proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale. To date, more than half of the 12 gene sequences from the Serum Institute of India PVT., Ltd have been transferred to Dyadic.

Dyadic entered into two animal health collaborations with two of the top four animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal diseases. One of the animal collaborations has been expanded to express additional proteins.
Dyadic entered into a sub-licensing agreement with Luina Bio Pty Ltd. an Australian-based drug development and contract manufacturing organization with more than 20 years of contract manufacturing experience, to develop and commercialize a number of targeted products for use in the prevention and treatment of various ailments for companion animals. Dyadic will receive a 20% equity stake in a new joint venture company, Novovet Pty Ltd ("Novovet"), plus royalties on future sales. To date, Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet.
Dyadic entered into a sub-licensing agreement with Alphazyme LLC ("Alphazyme"), a biotech company focused on producing molecular biology enzymes addressing markets for custom DNA and RNA molecules, genomic medicines and genetic testing. Dyadic will receive a 7.5% equity stake in Alphazyme upon the successful transfer of the C1 technology, and additional milestone payments and royalties will be payable to Dyadic upon successful commercialization of C1 expressed products. However, efforts to complete the last step of their internal qualification of C1 has been delayed partly due to the travel restriction under the COVID-19 pandemic.
Dyadic entered into two nonexclusive research licensing agreements with the University of Iowa and another one with an affiliate of a top 25 pharmaceutical company that supplies tools for life science research. The nonexclusive license allows for our collaborators to perform certain experiments and manipulations to C1 cell lines to create potential licensed products, and for any other internal noncommercial purpose determined by our collaborators to be necessary to evaluate the C1 technology. The collaborators will invest their own resources to evaluate C1 technology for research and their customers globally.

CORPORATE DEVELOPMENT

On April 17, Dyadic uplisted to the NASDAQ Capital Market and on July 1, Dyadic was added to the Russell Microcap® Index.

RESULTS FOR THE YEAR ENDED DECEMBER 31, 2019

At December 31, 2019, cash and cash equivalents were approximately $4.8 million compared to $2.4 million at December 31, 2018. The carrying value of investment grade securities, including accrued interest at December 31, 2019 was $31.2 million compared to $39.1 million at December 31, 2018.

Research and development revenue for the year ended December 31, 2019, increased to approximately $1,681,000 compared to $1,295,000 for the year ended December 31, 2018.

Cost of research and development revenue for the year ended December 31, 2019, increased to approximately $1,460,000 compared to $1,027,000 for the year ended December 31, 2018.

The increases in revenue and cost of research and development revenue for the year ended December 31, 2019 reflects ten research collaborations compared to six research collaborations for the year ended December 31, 2018.

Interest income for the year ended December 31, 2019, increased 10.1% to approximately $985,000 compared to $895,000 for the year ended December 31, 2018. The increase in interest income reflects the higher yield on the Company's investment grade securities, which are classified as held-to-maturity.

Research and development expenses for the year ended December 31, 2019 increased to approximately $3,088,000 compared to $2,102,000 for the year ended December 31, 2018. The increase primarily reflects the costs of additional internal research projects.

Research and development expenses – related party, for the year ended December 31, 2019, decreased to approximately $869,000 compared to $1,216,000 for the year ended December 31, 2018. The decrease is primarily due to the completion of the research service agreement with BDI in June 2019.

General and administrative expenses for the year ended December 31, 2019, increased 22.0% to approximately $5,520,000 compared to $4,523,000 for the year ended December 31, 2018. The increase principally reflects increases in noncash share-based compensation expenses of $717,000 related to 2019 stock options awards and options vested upon the April 2019 uplisting to the NASDAQ, business development and investor relations costs of $186,000, and insurance costs of $138,000, legal cost and NASDAQ uplisting expenses of $125,000, offset by reductions in executive compensation costs, including the separation of the Company's former CFO, of $168,000, which was a one-time expense in 2018.

Net loss for the year ended December 31, 2019 was approximately $8.3 million, or $(0.31) per share, compared to a net loss of $5.7 million, or $(0.21) per share, for the year ended December 31, 2018. The change was primarily due to the increases in general and administrative expenses of approximately $1.0 million and research and development expense of approximately $0.6 million in 2019, as well as the income tax benefit of approximately $1.0 million in 2018.

CONFERENCE CALL INFORMATION

Dyadic management will host a conference call today, Monday, March 30, 2020, at 5:00 PM ET to discuss the financial results for the year ended December 31, 2019. In order to participate in the conference call, please dial (877) 407-8033 for U.S./Canada callers and +(201) 689-8033 for International callers or use webcast link: https://www.webcaster4.com/Webcast/Page/2031/33572.

An archive of the webcast will be available approximately three hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com for a limited time. To access the replay of the webcast, please follow this link: https://www.webcaster4.com/Webcast/Page/2031/33572. A dial-in replay of the call will also be available to those interested until April 30, 2020. To access the replay, dial (877) 481-4010 for U.S./Canada callers and +(919) 882-2331 for International callers and enter replay pass code: 33572.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com/ for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at http://www.dyadic.com/.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: mailto:prawson@dyadic.com

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

 
 
 
 

 

 
Years Ended December 31,
 

 

 
2019
 
 
2018
 

 

 
 
 
 
 
 

Revenues:

 
 
 
 
 
 

Research and development revenue

 

1,681,076
 
 

1,295,451
 

 

 
 
 
 
 
 
 
 

Costs and expenses:

 
 
 
 
 
 
 
 

Costs of research and development revenue

 
 
1,459,701
 
 
 
1,027,278
 

Provision for contract losses

 
 
 
 
 
 

 

Research and development

 
 
3,087,597
 
 
 
2,101,628
 

Research and development – related party

 
 
868,720
 
 
 
1,215,536
 

General and administrative

 
 
5,519,922
 
 
 
4,522,676
 

Foreign currency exchange loss (gain), net

 
 
27,725
 
 
 
20,778
 

Total costs and expenses

 
 
10,963,665
 
 
 
8,887,896
 

 

 
 
 
 
 
 
 
 

Loss from operations

 
 
(9,282,589
)
 
 
(7,592,445
)

 

 
 
 
 
 
 
 
 

Interest income

 
 
984,930
 
 
 
894,532
 

 

 
 
 
 
 
 
 
 

Loss before income taxes

 
 
(8,297,659
)
 
 
(6,697,913
)

 

 
 
 
 
 
 
 
 

Provision for (benefit from) income taxes

 
 
10,306
 
 
 
(1,006,157
)

 

 
 
 
 
 
 
 
 

Net loss

 

(8,307,965
)
 

(5,691,756
)

 

 
 
 
 
 
 
 
 

Basic and diluted net loss per common share

 

(0.31
)
 

(0.21
)

 

 
 
 
 
 
 
 
 

Basic and diluted weighted-average common shares outstanding

 
 
27,003,695
 
 
 
27,673,300
 

 
 
 
 
 
 
 
 
 

See Notes to Condensed Consolidated Financial Statements in Part I of Dyadic's Annual Report on Form 10-K filed with Securities and Exchange Commission on March 30, 2020.

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

 
 
 
 

 

 
December 31,
 

 

 
2019
 
 
2018
 

Assets

 
 
 
 
 
 

Current assets:

 
 
 
 
 
 

Cash and cash equivalents

 

4,823,544
 
 

2,386,314
 

Short-term investment securities

 
 
29,399,146
 
 
 
38,816,441
 

Interest receivable

 
 
329,711
 
 
 
294,240
 

Accounts receivable

 
 
558,530
 
 
 
318,744
 

Income tax receivable

 
 
250,308
 
 
 
506,866
 

Prepaid research and development

 
 

 
 
 
253,446
 

Prepaid expenses and other current assets

 
 
277,999
 
 
 
172,001
 

Total current assets

 
 
35,639,238
 
 
 
42,748,052
 

 

 
 
 
 
 
 
 
 

Non-current assets:

 
 
 
 
 
 
 
 

Long-term investment securities

 
 
1,511,636
 
 
 

 

Long-term income tax receivables

 
 
250,308
 
 
 
500,616
 

Other assets

 
 
51,314
 
 
 
52,139
 

Total assets

 

37,452,496
 
 

43,300,807
 

 

 
 
 
 
 
 
 
 

Liabilities and stockholders' equity

 
 
 
 
 
 
 
 

Current liabilities:

 
 
 
 
 
 
 
 

Accounts payable

 

943,378
 
 

309,060
 

Accrued expenses

 
 
566,003
 
 
 
399,576
 

Deferred research and development obligations

 
 
78,644
 
 
 
141,002
 

Total current liabilities

 
 
1,588,025
 
 
 
849,638
 

 

 
 
 
 
 
 
 
 

Commitments and contingencies

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

Stockholders' equity:

 
 
 
 
 
 
 
 

Preferred stock, $.0001 par value:

 
 

 
 
 

 

Authorized shares – 5,000,000; none issued and outstanding

 
 

 
 
 

 

Common stock, $.001 par value:

 
 
 
 
 
 
 
 

Authorized shares – 100,000,000; issued shares – 39,612,659 and 38,996,988, outstanding shares – 27,359,157 and 26,713,486 as of December 31, 2019 and 2018, respectively

 
 
39,613
 
 
 
38,967
 

Additional paid-in capital

 
 
96,105,851
 
 
 
94,385,230
 

Treasury stock, shares held at cost – 12,253,502

 
 
(18,929,915
)
 
 
(18,929,915
)

Accumulated deficit

 
 
(41,351,078
)
 
 
(33,043,113
)

Total stockholders' equity

 
 
35,864,471
 
 
 
42,451,169
 

Total liabilities and stockholders' equity

 

37,452,496
 
 

43,300,807
 

 
 
 
 
 
 
 
 
 

See Notes to Condensed Consolidated Financial Statements in Part I of Dyadic's Annual Report on Form 10-K filed with Securities and Exchange Commission on March 30, 2020.

SOURCE: Dyadic International, Inc.

ReleaseID: 583161

Practical Business and Insurance Considerations for Hotels and Restaurants during the Covid-19 Crisis

MIAMI, FL / ACCESSWIRE / March 30, 2020 / COVID-19 has thrown our way of living into treacherous and unchartered waters. With each passing day, the scare of this novel virus is causing government officials at every level to react with decisions that effectively strip our ability to work, shop, play and interact normally in order to slow or prevent the spread of this viral outbreak.

This ripple effect includes the requirement of closing restaurants, creating an absent and fearful workforce with obligations for their employees' compensation, disruption of supply chains, cancellations of reservations and bookings.

Restaurants and hotels are undoubtedly stressed to find ways to manage decreased cash flows and stop the bleeding losses to recoup or minimize the damage for their losses of income, assets, and brand value during and in the aftermath of this unforeseen ‘tragedy.'

Business interruption insurance is an extremely important type of coverage in an insurance policy which is intended to cover for lost income sustained as a result of a covered peril in order to allow for the continuity of your business into the future.

Often, specific exclusion language exists in a policy that makes the case seem completely defeated and untenable. Insurance companies will continue to seek an escape from their contractual obligations, but there are creative legal strategies that can help navigate the treacherous waters of these obstructive defenses.

Civil Authority coverage, for instance, applies when a local, state, or federal government mandates to limit access to any aspect of your business which is critical to a business owner's ability to conduct his normal operations.

Contingent Business Interruption Insurance is when the loss is indirect as caused, for instance, by the inability of a supplier to perform his obligations with the Insured (business owner) due to no fault of his own and is considered covered by the business owner's insurance policy.

Under the contract doctrines of Impossibility of Performance and Frustration of Purpose, a party is discharged from performing a contractual obligation due to no fault of their own, if it is impossible or futile to perform, the party could neither have foreseen the risk at the time of entering into the contract, or could they have prevented the event(s) in question from occurring in the first place.

Force Majeure is a defense to contractual obligations to perform and arises when parties cannot reasonably foresee nor control an event, which prevents either party to perform their contractual obligations. An Act of God may be considered as force majeure; it refers to a natural phenomenon that is exceptional, inevitable, and irresistible, and which its effects could not be prevented or avoided by the exercise of due care.

These and other legal doctrines provide legal defenses for business owners not to have to continue to perform their contractual obligations.

ABOUT ZARCO LAW

Zarco Einhorn Salkowski & Brito, P.A. is a leading business transaction and litigation law firm. Located in Miami, our attorneys serve clients in Florida, throughout the United States and internationally. Our attorneys include former economists, bankers and accountants who are able to look beyond your legal issues to craft solutions that are practical, expeditious, and highly beneficial to your company. We are recognized as one of the top franchise law firms in the United States, and we are repeatedly awarded a "Best Law Firms" ranking in U. S. News & World Report. Our firm's senior partners, Robert Zarco, Robert Einhorn, Robert Salkowski and Alejandro Brito are repeatedly awarded as "Super Lawyers" and "Best Lawyers" for many years. We handle all aspects of franchise, licensing and distribution law, as well as complex commercial and insurance disputes and transactions. www.ZarcoLaw.com

CONTACT:
Robert Zarco, Esq.
Zarco, Einhorn, Salkowski & Brito, P.A.,
Attorneys at Law
305-798-4777

SOURCE: Zarco, Einhorn, Salkowski & Brito, P.A

ReleaseID: 583163

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SSL, ANAB and HAFC

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Sasol Limited (NYSE:SSL)

Investors Affected: March 10, 2015 – January 13, 2020

A class action has commenced on behalf of certain shareholders in Sasol Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Sasol had conducted insufficient due diligence into, and failed to account for multiple issues with, the Lake Charles Chemicals Project ("LCCP"), as well as the true cost of the project; (ii) construction and operation of the LCCP was consequently plagued by control weaknesses, delays, rising costs, and technical issues; (iii) these issues were exacerbated by Sasol's top-level management, who engaged in improper and unethical behavior with respect to financial reporting for the LCCP and the project's oversight; (iv) all the foregoing was reasonably likely to render the LCCP significantly more expensive than disclosed and negatively impact the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/sasol-limited-loss-submission-form/?id=5853&from=1

AnaptysBio, Inc. (NASDAQ:ANAB)

Investors Affected: October 10, 2017 – November 7, 2019

A class action has commenced on behalf of certain shareholders in AnaptysBio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/anaptysbio-inc-loss-submission-form/?id=5853&from=1

Hanmi Financial Corporation (NASDAQ:HAFC)

Investors Affected: August 12, 2019 – January 28, 2020

A class action has commenced on behalf of certain shareholders in Hanmi Financial Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the $40.7 million troubled loan that the Company disclosed on conference calls would necessitate further and future specific provisions for the Company – in the millions; (2) the same $40.7 million troubled loan would necessitate the Company to appraise and take personal property securing a portion of the amount of the loan; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/hanmi-financial-corporation-loss-submission-form/?id=5853&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 583165

Meet the Dentist Perfecting Celebrity Smiles; Dr. Matthew Kaiser

LOS ANGELES, CA / ACCESSWIRE / March 30, 2020 / This dentist's biggest fear was going out on his own and opening his dream office. Now he plans on doing exactly that in December of 2020.

Dr. Matthew Kasiar was born and raised in southern Illinois. He was the youngest of three children. His dad was a pharmacist and owned and operated a small pharmacy in their hometown.

It was being around his dad and the pharmacy that Dr. Kasiar developed a love for the healthcare system. He witnessed how his dad was able to help people and the satisfaction that it gave him. Dr. Kasiar's love of design and healthcare led him into the field of dentistry where he excelled as a student graduating with honors. Over the past 14 years Dr. Kasiar has been blessed to help many patients get the smile they've always wanted.

Currently, Dr. Kasiar uses virtual consults as a way to connect with potential patients all over the country. They are able to submit 2 pictures and within a week they receive a personal video consultation from Dr. Kasiar discussing treatment options and cost. Dr. Kasiar believes being transparent is the key. Patients want to know who they can trust, how long will it take, and how much it costs. He answers all those questions in the virtual consult.

Dealing With Competition

In order for his company to stand out from the crowd, Dr. Kasiar places huge emphasis on customer service. "I feel like the healthcare industry as a whole lacks quality customer service," he says.

At his practice, they don't want patients to feel like an inconvenience instead of a patient. "We make each patient feel like they are the only one there. We are 100% focused on their needs and go above and beyond to exceed expectations. They aren't just patients, they are our family," states Dr. Kasiar.

Building a Business as an Entrepreneur

According to Dr. Kasiar, the biggest challenge of entrepreneurship is deciding to take action on your dream. "There are a lot of great dreams and ideas out there that never make it to reality. Most often it's because of a fear of failing. I say that because I was fearful too. But I knew I would always wonder ‘what if' if I never tried," Dr. Kasiar states.

He also believes that having the right mindset is equally important. Dr. Kasiar believes that if you go into business with a negative attitude you will get negative results. However, he's not saying that having a positive attitude will be enough. Problems will come up. But it's that positive mindset that will keep you motivated and focused to overcome them.

Scaling A Business

Dr. Kasiar believes there are two things to keep in mind when scaling a business.

The first is to define your core customer. You want to find people who can use your service, and are willing to pay for it. You'll then want to make sure they don't start drama. And as a bonus, you'll want to figure out if they are willing to refer other clients like themselves.

The second is to solve one major issue extremely well. Oftentimes, Dr. Kasiar notices that companies are selling anything to anyone without a real plan. He believes that if you want to grow a real business, you have to double down on solving one specific problem for a specific market. And if you can become an expert at that one thing you'll be able to scale in that market because there's likely more than enough customers in that niche. After all, the world is huge!

What Success Looks Like to Dr. Kasiar

Dr. Kasiar believes that his biggest success has been his ability to give back to his community through free dental days. "We've been able to serve many people who otherwise wouldn't have been able to receive treatment. It's amazing to see all the competing doctors come together for a common cause and serve our community. It truly is a rewarding experience for everyone!"

As for his legacy, Dr. Kasiar wants to be known as the dentist to come to for a smile makeover. He seeks to build confidence for every patient he's worked with so that they can be the best version of themselves. And he wants to be known for helping teach other dentists the art of designing smiles.

Dr. Kasiar's practice is located in Franklin, TN. If you would like to receive a virtual consult from Dr. Kasiar, visit his website!

CONTACT:

Trenten Huss
HighKey Agency
tjh@highkeyagency.com
(204) 698-6281

SOURCE: HighKey Agency

ReleaseID: 583160

Aptinyx, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Aptinyx, Inc. (NASDAQ:APTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60871

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582945

Eastside Distilling, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Eastside Distilling, Inc. (NASDAQ:EAST) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60931

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582944

Venus Concept Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Venus Concept Inc (NASDAQ:VERO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60726

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582940

USIO, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / USIO, Inc. (NASDAQ:USIO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60927

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582939